BioSpace News Archive

Be Biopharma, a pioneer in the discovery and development of Engineered B Cell Medicines, announced the closing of a $130 million financing, bringing the total investment in the Company to over $180 million.

Evox Therapeutics Ltd announces the appointment of Peter Jones as Vice President of CMC.

Marinus Pharmaceuticals Announces Publication in The Lancet Neurology of ZTALMY ® (ganaxolone) Phase 3 Marigold Trial Results.

Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced Twirla prescription data for the first quarter 2022.

Surface Oncology today announced the initiation of two Phase 2 clinical studies evaluating SRF388, a potential first-in-class antibody against IL-27.

CareDx, Inc. announced that it has delivered over 200,000 AlloMap® or AlloSure® results for over 30,000 heart transplant recipients.

Applied Genetic Technologies Corporation today announced that Sue Washer, President & Chief Executive Officer, will present at the Alliance for Regenerative Medicine Cell & Gene Meeting on the Mediterranean in Barcelona, Spain on Thursday, April 21 at 9:30 PM CEST / 3:30 PM ET.

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today reported the positive outcome of its first data and safety monitoring board (DSMB) meeting for NAVIGATE, its seamless, adaptive, phase 2b/3 study of belapectin in patients with liver cirrhosis caused by non-alcoholic steatohepatitis (NASH).

AbbVie (NYSE: ABBV) will announce its first-quarter 2022 financial results on Friday, April 29, 2022, before the market opens.

Amyris, Inc. successfully hosted an in-person investor event following the Company’s Nasdaq Opening Bell Ringing Ceremony.